NLF20: An antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 170-180

  Papareddy, Praveen ^a   Kasetty, Gopinath ^a   Kalle, Martina ^a   Bhongir, Ravi K V ^a   Mörgelin, Matthias ^a   Schmidtchen, Artur ^a,b   Malmsten, Martin ^c  

^a LUND UNIVERSITY   (Sweden)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; GAMMA INTERFERON; INTERLEUKIN 10; LACTATE DEHYDROGENASE; LEVOFLOXACIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NLF 20; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ELECTRON MICROSCOPY; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; KERATINOCYTE; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPTIC SHOCK; STREPTOCOCCUS PYOGENES; SURVIVAL; ANIMAL; C57BL MOUSE; CELL MEMBRANE; DRUG EFFECTS; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MALE; MICROBIAL SENSITIVITY TEST; PERMEABILITY; PHYSIOLOGY; PSEUDOMONAS INFECTIONS; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE; FUNGI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MALE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; PERMEABILITY; PSEUDOMONAS INFECTIONS; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84960080828     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv322     Document Type: Article

References (50)

1. Savoia D. New perspectives in the management of Pseudomonas aeruginosa infections. Future Microbiol 2014; 9: 917-28.
2. Fothergill JL, Winstanley C, James CE. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev Anti Infect Ther 2012; 10: 219-35.
3. Morita Y, Tomida J, Kawamura Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol 2014; 4: 422.
4. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006; 6: 468-72.
5. Blondelle SE, Lohner K. Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure-activity relationship studies. Biopolymers 2000; 55: 74-87.
6. Sajjan US, Tran LT, Sole N et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum fromcystic fibrosis patients. Antimicrob Agents Chemother 2001; 45: 3437-44.
7. Fernandez-Lopez S, Kim HS, Choi EC et al. Antibacterial agents based on the cyclic D,L-a-peptide architecture. Nature 2001; 412: 452-5.
8. Hilpert K, Volkmer-Engert R, Walter T et al. High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 2005; 23: 1008-12.
9. Taboureau O, Olsen OH, Nielsen JD et al. Design of novispirin antimicrobial peptides by quantitative structure-activity relationship. Chem Biol Drug Des 2006; 68: 48-57.
10. Jenssen H, Lejon T, Hilpert K et al. Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa. Chem Biol Drug Des 2007; 70: 134-42.
11. Pasupuleti M, Walse B, Svensson B et al. Rational design of antimicrobial C3a analogues with enhanced effects against staphylococci using an integrated structure and function-based approach. Biochemistry 2008; 47: 9057-70.
12. Papareddy P, Rydengard V, Pasupuleti M et al. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 2010; 6: e1000857.
13. Pasupuleti M, Walse B, Nordahl EA et al. Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. J Biol Chem 2007; 282: 2520-8.
14. Nordahl EA, Rydengard V, Nyberg P et al. Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci USA 2004; 101: 16879-84.
15. Nordahl EA, Rydengard V, Mörgelin M et al. Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 2005; 280: 34832-9.
16. Malmsten M, Davoudi M, Schmidtchen A. Bacterial killing by heparinbinding peptides from PRELP and thrombospondin. Matrix Biol 2006; 25: 294-300.
17. Malmsten M, Davoudi M, Walse B et al. Antimicrobial peptides derived from growth factors. Growth Factors 2007; 25: 60-70.
18. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
19. Hilchie AL, Wuerth K, Hancock RE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 2013; 9: 761-8.
20. Choi KY, Chow LN, Mookherjee N. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun 2012; 4: 361-70.
21. Papareddy P, Kalle M, Sorensen OE et al. The TFPI-2 derived peptide EDC34 improves outcome of Gram-negative sepsis. PLoS Pathog 2013; 9: e1003803.
22. Kalle M, Papareddy P, Kasetty G et al. Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis. PLoS One 2012; 7: e51313.
23. Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 2012; 10: 243-54.
24. Kalle M, Papareddy P, Kasetty G et al. Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol 2013; 190: 6303-10.
25. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008; 3: 163-75.
26. Andersson E, Rydengad V, Sonesson A et al. Antimicrobial activities of heparin-binding peptides. Eur J Biochem 2004; 271: 1219-26.
27. Lehrer RI, Rosenman M, Harwig SS et al. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 1991; 137: 167-73.
28. Pollock JS, Forstermann U, Mitchell JA et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-4.
29. Papareddy P, Kalle M, Bhongir RK et al. Antimicrobial effects of helix D-derived peptides of human antithrombin III. J Biol Chem 2014; 289: 29790-800.
30. Fritsche TR, Rhomberg PR, Sader HS et al. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J Antimicrob Chemother 2008; 61: 1092-8.
31. Turner J, Cho Y, Dinh NN et al. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998; 42: 2206-14.
32. Malmsten M, Kasetty G, Pasupuleti M et al. Highly selective end-tagged antimicrobial peptides derived from PRELP. PLoS One 2011; 6: e16400.
33. Shaykhiev R, Beisswenger C, Kandler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005; 289: L842-8.
34. Kalle M, Papareddy P, Kasetty G et al. A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection. PLoS One 2014; 9: e102577.
35. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013; 39: 559-66.
36. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43.
37. Abraham E, Anzueto A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-33.
38. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-a MAb Sepsis Study Group. JAMA 1995; 273: 934-41.
39. Fisher CJ Jr, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-702.
40. Goldie AS, Fearon KC, Ross JA et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995; 274: 172-7.
41. Opal SM, Fisher CJ Jr, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-24.
42. Fisher CJ Jr, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.
43. Dhainaut JF, Tenaillon A, Hemmer M et al. Confirmatory plateletactivating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26: 1963-71.
44. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
45. Roemisch J, Gray E, Hoffmann JN et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-70.
46. Hoffmann JN, Vollmar B, Laschke MW et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-52.
47. Bernard GR, Wheeler AP, Russell JA et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912-8.
48. Arons MM, Wheeler AP, Bernard GR et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 1999; 27: 699-707.
49. Ziegler EJ, Fisher CJ Jr, Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-36.
50. Singh S, Papareddy P, Kalle M et al. Importance of lipopolysaccharide aggregate disruption for the anti-endotoxic effects of heparin cofactor II peptides. Biochim Biophys Acta 2013; 1828: 2709-19.